Publications by authors named "A M Kolomeyer"
Purpose: To evaluate if dual angiopoietin-2 (Ang-2)/VEGF-A inhibition with faricimab resulted in greater macular leakage resolution versus aflibercept in patients with diabetic macular edema (DME).
Design: Post hoc analysis of macular leakage assessments prespecified in the YOSEMITE/RHINE (NCT03622580/NCT03622593) phase III trials.
Participants: Adults with visual acuity loss due to center-involving DME.
To compare the modeled costs of the Protocol AC bevacizumab-first treatment protocol (with a switch to aflibercept for sub-responders) with real-world costs for treatment-naïve patients with diabetic macular edema (DME) over a 2-year period. Published data from the Diabetic Retinopathy Clinical Research Network (DRCR) Protocol AC bevacizumab-first arm (154 eyes) were used to model 2-year treatment costs. Real-world costs were modeled using data from the Vestrum Health electronic medical records database from a 2016 to 2018 cohort of treatment-naïve eyes with DME (n = 1062) treated with antivascular endothelial growth factor monotherapy.
View Article and Find Full Text PDFArticle Synopsis
- * A retrospective study analyzed 18 eyes from patients aged 46 to 93 with chronic NIU-PS who received the FAi, observing factors like previous treatments, uveitis recurrence rates, and visual acuity over an average follow-up of 16.5 months.
- * Results indicated 61% of eyes had more than five uveitis recurrences prior to treatment, but the majority showed reduced recurrence and improved vision and anatomical measures post-FAi.
Purpose: The aim of this study was to describe a case of bullous variant of central serous chorioretinopathy (CSR) in Goodpasture disease (GD) compared with an identical twin without GD and summarize the literature on ocular manifestations of GD.
Methods: This was an interventional/observational case report and literature review.
Results: A 46-year-old White woman with a history of GD presented with decreased vision.
The 0.19-mg Fluocinolone Acetonide Implant for the Treatment of Diabetic Macular Edema: An Expert Consensus.
Ophthalmic Surg Lasers Imaging Retina
March 2023
Background And Objective: To better understand the level of agreement among retina specialists on the role of inflammation in diabetic retinopathy (DR) and diabetic macular edema (DME), and the use of 0.19-mg fluocinolone acetonide (FAc) implant in DME treatment, a consensus survey was drafted and disseminated to retina specialists across the United States.
Materials And Methods: Using the modified Delphi method, a list of 12 consensus statements were generated by the coauthors based on short-answer responses to an initial survey.